Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies

No abstract is available for this paper.

• Publication year

  2005

• Venue

  International Clinical Psychopharmacology

• Publication date

  2005-05-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1097/00004850-200505000-00001PMID 15812261
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• THE CANADIAN JOURNAL OF PSYCHIATRY

  2017cited by this paper
• Early clinical experience with risperidone long-acting injection: a prospective, 6-month follow-up of 100 patients.

  2004cited by this paper
• A Randomized Open-Label Study of the Impact of Quetiapine Versus Risperidone on Sexual Functioning

  2004cited by this paper
• The impact of weight gain associated with atypical antipsychotic use in schizophrenia

  2004cited by this paper
• Improvements in stable patients with psychotic disorders switched from oral conventional antipsychotics therapy to long-acting risperidone

  2004cited by this paper
• Health-related quality of life in patients with schizophrenia during treatment with long-acting, injectable risperidone.

  2004cited by this paper
• Risperidone versus Conventional Antipsychotics for Schizophrenia and Schizoaffective Disorder

  2004cited by this paper
• Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia.

  2004influential reference
• Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia.

  2004cited by this paper
• A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia.

  2004influential reference
• Risperidone long-acting injection: the first 50 patients

  2004cited by this paper
• Population-based incidence rates and risk factors for type 2 diabetes in white individuals: the Bruneck study.

  2004influential reference
• Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidone

  2004cited by this paper
• Consensus development conference on antipsychotic drugs and obesity and diabetes.

  2004cited by this paper
• Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia.

  2004influential reference
• Risperidone long-acting injection

  2003cited by this paper
• Long-term side effects of SSRIs: sexual dysfunction and weight gain.

  2003cited by this paper
• Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials.

  2003cited by this paper
• Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic.

  2003influential reference
• SF-36 health survey: Manual and interpretation guide

  2003cited by this paper
• Overview of partial compliance.

  2003influential reference
• Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic.

  2003cited by this paper
• Partial compliance and patient consequences in schizophrenia: our patients can do better.

  2003cited by this paper
• Predictors of noncompliance in patients with schizophrenia.

  2002influential reference
• Antipsychotic medication adherence: is there a difference between typical and atypical agents?

  2002cited by this paper
• A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia.

  2002cited by this paper
• Relapse and Rehospitalisation Rates in Patients with Schizophrenia

  2002cited by this paper
• Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder.

  2002cited by this paper
• Extrapyramidal side effects are unacceptable.

  2001cited by this paper
• Negative symptoms of schizophrenia and compliance with medication.

  2001cited by this paper
• Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia.

  2001cited by this paper
• Progress defined--short-term efficacy, long-term effectiveness.

  2001influential reference
• Injections of depot antipsychotic medications in patients suffering from schizophrenia: do they hurt?

  2001cited by this paper
• Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder.

  1999cited by this paper
• Reliability, validity, and application of the medical outcomes study 36-item short-form health survey (SF-36) in schizophrenic patients treated with olanzapine versus haloperidol.

  1999cited by this paper
• Switching from depot antipsychotics to risperidone: results of a study of chronic schizophrenia. The Schizophrenia Treatment & Assessment Group.

  1999cited by this paper
• Excess mortality of mental disorder

  1998cited by this paper
• Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy.

  1998influential reference
• Facilitating compliance with antipsychotic medication.

  1998cited by this paper
• The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials.

  1997influential reference
• Excess mortality of schizophrenia

  1997cited by this paper
• Delayed normalization of central D2 dopamine receptor availability after discontinuation of haloperidol decanoate. Preliminary findings.

  1997cited by this paper
• The MOS 36-Item Short form Health Survey

  1997cited by this paper
• Determinants of medication compliance in schizophrenia: empirical and clinical findings.

  1997cited by this paper
• Predicting the "revolving door" phenomenon among patients with schizophrenic, schizoaffective, and affective disorders.

  1995cited by this paper
• Identifying modifiable risk factors for rehospitalization: a case-control study of seriously mentally ill persons in Mississippi.

  1995cited by this paper
• Drs. Sullivan and Youngner Reply

  1995cited by this paper
• Complications at site of injection of depot neuroleptics

  1995cited by this paper
• Long Term Depot Antipsychotics

  1994cited by this paper
• Depot antipsychotic drugs. Place in therapy.

  1994cited by this paper
• Prevention of relapse in chronic schizophrenic patients.

  1993cited by this paper
• The MOS 36‐Item Short‐Form Health Survey (SF‐36): II. Psychometric and Clinical Tests of Validity in Measuring Physical and Mental Health Constructs

  1993cited by this paper
• The MOS 36-ltem Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection

  1992cited by this paper
• The MOS 36-Item Short-Form Health Survey (SF-36)

  1992cited by this paper
• North American Association for the Study of Obesity

  1991cited by this paper
• Frequent rehospitalization and noncompliance with treatment.

  1988cited by this paper
• Comparative efficacy of long-acting depot and oral neuroleptic medications in preventing schizophrenic recidivism.

  1987cited by this paper
• The positive and negative syndrome scale (PANSS) for schizophrenia.

  1987cited by this paper

• Clinical Utility of Long-Acting Injectable Risperidone in Schizophrenia and Bipolar I Disorder: A Review of Clinical Studies

  2025cites this paper
• Clinical, Quality of Life, and Health Care Utilization Outcomes of Switching the Administration Route of Antipsychotic Medications Among People With Schizophrenia Spectrum Disorder: A Systematic Review and Meta-Analysis

  2024cites this paper
• Second Generation Long-Acting Injectable Antipsychotics in Schizophrenia: The Patient’s Subjective Quality of Life, Well-Being, and Satisfaction

  2023cites this paper
• [Second-generation long-acting injectable antipsychotics in clinical practice].

  2022cites this paper
• Exploring the association between social behaviour, trust, and its neural correlates in first episode psychosis patients and in individuals at clinical high risk for psychosis

  2021cites this paper
• Therapeutic Drug Monitoring of Long-Acting Injectable Antipsychotic Drugs.

  2020cites this paper
• Trend survey on adverse event profiles of antipsychotic long-acting injections and oral agents using the Japanese adverse drug event report database.

  2020cites this paper
• Social Mindfulness and Psychosis: Neural Response to Socially Mindful Behavior in First-Episode Psychosis and Patients at Clinical High-Risk

  2019cites this paper
• Discontinuation rates during long‐term, second‐generation antipsychotic long‐acting injection treatment: A systematic review

  2019cites this paper
• Comparison of Paliperidone Palmitate and Second-Generation Oral Antipsychotics in Terms of Medication Adherence, Side Effects, and Quality of Life.

  2019cites this paper
• Анализ длительной терапии препаратом Ксеплион больных шизофренией

  2018cites this paper
• Learning to trust: social feedback normalizes trust behavior in first-episode psychosis and clinical high risk

  2018cites this paper
• Switching from oral atypical antipsychotic monotherapy to paliperidone palmitate once-monthly in non-acute patients with schizophrenia: A prospective, open-label, interventional study

  2016cites this paper
• Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life

  2016cites this paper
• Remission and employment status in schizophrenia and other psychoses: One-year prospective study in Croatian patients treated with risperidone long acting injection.

  2016influential citation
• Schizophrenia-spectrum patients treated with long-acting injectable risperidone in real-life clinical settings: functional recovery in remitted versus stable, non-remitted patients (the EVeREST prospective observational cohort study)

  2016cites this paper
• Pharmacoeconomics of long-acting atypical antipsychotics for acutely relapsed chronic schizophrenia in Finland

  2016cites this paper
• Cross-sectional comparison of first-generation antipsychotic long-acting injections vs risperidone long-acting injection: patient-rated attitudes, satisfaction and tolerability

  2016cites this paper
• Effects of paliperidone extended release on functioning level and symptoms of patients with recent onset schizophrenia: An open-label, single-arm, flexible-dose, 12-months follow-up study

  2015cites this paper
• A Post-Authorisation Safety Survey Evaluating Risperidone Long-Acting Injectable in Romania

  2015cites this paper
• Treatment response, safety, and tolerability of paliperidone extended release treatment in patients recently diagnosed with schizophrenia

  2015cites this paper
• Enhancing adherence, subjective well-being and quality of life in patients with schizophrenia: which role for long-acting risperidone?

  2015cites this paper
• Lost in Translation: Exposure Misclassification when Relying on Days Supply in Pharmacy Claims Data

  2014cites this paper
• Almost All Antipsychotics Result in Weight Gain: A Meta-Analysis

  2014cites this paper
• A prospective flexible-dose study of paliperidone palmitate in nonacute but symptomatic patients with schizophrenia previously unsuccessfully treated with oral antipsychotic agents.

  2014cites this paper
• Pharmacoeconomics of depot antipsychotics for treating chronic schizophrenia in Sweden

  2014cites this paper
• Paliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychotics

  2013cites this paper
• Efficacy and safety of long acting injectable atypical antipsychotics: a review.

  2013cites this paper
• Costo-efficacia di risperidone iniettabile a rilascio prolungato nel trattamento della schizofrenia in Italia

  2013cites this paper
• Adverse Effects Associated with Second‐Generation Antipsychotic Long‐Acting Injection Treatment: A Comprehensive Systematic Review

  2013cites this paper
• Cost-Utility Analysis of Depot Atypical Antipsychotics for Chronic Schizophrenia in Croatia.

  2013cites this paper
• Long-Acting Injectable Formulations of New-Generation Antipsychotics: A Review from a Clinical Perspective

  2013cites this paper
• Economic and clinical comparison of atypical depot antipsychotic drugs for treatment of chronic schizophrenia in the Czech Republic

  2013cites this paper
• [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].

  2013cites this paper
• Should long-acting (depot) antipsychotics be used in early schizophrenia? A systematic review

  2013cites this paper
• Long‐acting injectable antipsychotics in early psychosis: a literature review

  2013cites this paper
• Long-Acting Injectable Antipsychotics: Evidence of Effectiveness and Use

  2013cites this paper
• Role of Long-Acting Injectable Second-Generation Antipsychotics in the Treatment of First-Episode Schizophrenia: A Clinical Perspective

  2012cites this paper
• The cost–effectiveness of risperidone long-acting injection in the treatment of schizophrenia

  2012cites this paper
• Long-Acting Injectable Risperidone for the Treatment of Schizophrenia

  2012cites this paper
• THE IMPACT OF TREATMENT WITH RISPERIDONE LONG-ACTING INJECTION ON THE BELGIAN HEALTHCARE SYSTEM: RESULTS FROM A BUDGET IMPACT MODEL

  2012cites this paper
• Long-acting antipsychotic drugs for the treatment of schizophrenia: use in daily practice from naturalistic observations

  2012cites this paper
• Effects of controlled-release formulations of atypical antipsychotics on functioning and quality of life of schizophrenic individuals

  2012influential citation
• Long-Acting Injectable Antipsychotics in First-Episode Schizophrenia

  2012cites this paper
• Switching Patients with Stable Schizophrenia or Schizoaffective Disorder from Olanzapine to Risperidone Long-Acting Injectable

  2012cites this paper
• Long-acting risperidone and oral antipsychotics in unstable schizophrenia.

  2011cites this paper
• Assessment of effectiveness measures in patients with schizophrenia initiated on risperidone long-acting therapy: the SOURCE study results

  2011cites this paper
• Risperidone Long-Acting Injection: Safety and Efficacy in Elderly Patients with Schizophrenia

  2011cites this paper
• How do clinical trial participants compare to other patients with schizophrenia?

  2011influential citation
• [Evaluation of prescription practices of long acting injectable risperidone in French hospitals].

  2011cites this paper
• Clinical relevance of findings in trials of antipsychotics: systematic review

  2011cites this paper
• Effectiveness of injectable risperidone long-acting therapy for schizophrenia: data from the US, Spain, Australia, and Belgium

  2011cites this paper
• Long-Term Safety and Tolerability of Open-Label Olanzapine Long-Acting Injection in the Treatment of Schizophrenia: 190-Week Interim Results

  2011cites this paper
• A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia

  2011cites this paper
• Clinical outcomes of long-acting injectable risperidone in patients with schizophrenia: six-month follow-up from the Electronic Schizophrenia Treatment Adherence Registry in Latin America

  2010cites this paper
• Risperidone long-acting injectable (Risperdal Consta ® )

  2010cites this paper
• Long-term pharmacotherapy of schizophrenic patients: Achievements, unsolved needs and future perspectives with special focus on long-acting injectable second generation antipsychotics

  2010cites this paper
• Haloperidol decanoate and long-acting injectable risperidone: subjective experience of outpatients with schizophrenia

  2010cites this paper
• Long-acting atypical injectable antipsychotics in the treatment of schizophrenia: safety and tolerability review

  2010cites this paper
• Establishing remission and good clinical functioning in schizophrenia: Predictors of best outcome with long-term risperidone long-acting injectable treatment

  2010cites this paper
• Prospective, Open Study of Long-Acting Injected Risperidone versus Oral Antipsychotics in 88 Chronically Psychotic Patients

  2010cites this paper
• Risperidone long-acting therapy in stable patients with recently diagnosed schizophrenia

  2010cites this paper
• Risperidone long-acting injectable (Risperdal Consta®) for maintenance treatment in patients with bipolar disorder

  2010cites this paper
• Switching stable patients with schizophrenia from depot and oral antipsychotics to long‐acting injectable risperidone: reasons for switching and safety

  2010influential citation
• clinical outcomes of long-acting injectable risperidone in patients with schizophrenia: six-month follow-up from the electronic schizophrenia Treatment Adherence registry in Latin America

  2010cites this paper
• Long-acting injectable risperidone and metabolic ratio: a possible index of clinical outcome in treatment-resistant schizophrenic patients

  2010cites this paper
• Safety and efficacy of long-acting injectable risperidone in daily practice: an open-label, noninterventional, prospective study in schizophrenia and related disorders

  2010cites this paper
• Does Oral Antipsychotic Pre-Treatment Influence Outcome of a Switch to Long-Acting Injectable Risperidone in Patients with Schizophrenia?

  2010cites this paper
• Switching stable patients with schizophrenia from depot and oral antipsychotics to long‐acting injectable risperidone: efficacy, quality of life and functional outcome

  2010influential citation
• Experience with injectable long-acting risperidone in long-term therapy after an acute episode of schizophrenia: the SPHERE Study

  2009cites this paper
• Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: Results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR)

  2009cites this paper
• Effectiveness a medio termine di un nuovo antipsicotico atipico a rilascio prolungato: Uno studio osservazionale per obbiettivi

  2009cites this paper
• Pharmacokinetics and efficacy of a direct switch from conventional depot to risperidone long‐acting injection in Chinese patients with schizophrenic and schizoaffective disorders

  2009cites this paper
• Use of long-acting risperidone in psychiatric disorders: focus on efficacy, safety and cost–effectiveness

  2009cites this paper
• Dosing patterns in Europe: Efficacy and safety of risperidone long-acting injectable in doses of 25, 37.5 and 50 mg

  2009cites this paper
• Efficacy and safety of risperidone long-acting injection in elderly people with schizophrenia

  2009cites this paper
• Adherence to risperidone long‐acting injection dosing recommendations

  2009cites this paper
• Second-generation antipsychotic long-acting injections: Systematic review

  2009cites this paper
• A descriptive, open-label, long-term follow-up survey of psychotic patients receiving risperidone long-acting injectable: Preliminary results

  2009cites this paper
• Remission in schizophrenia: one‐year Italian prospective study of risperidone long‐acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder

  2009influential citation
• Restless legs syndrome caused by quetiapine successfully treated with ropinirole in 2 patients with bipolar disorder.

  2008cites this paper
• Risperidone long-acting injection: a review of its long term safety and efficacy

  2008cites this paper
• Identifying the profile of optimal candidates for antipsychotic depot therapy A cluster analysis.

  2008cites this paper
• Improved symptom control, functioning and satisfaction in French patients treated with long-acting injectable risperidone.

  2008cites this paper
• Use of depot antipsychotic medications for medication nonadherence in schizophrenia.

  2008cites this paper
• Risperidone long-acting injectable for maintenance therapy in bipolar disorder: An open-label pilot study

  2008cites this paper
• Long-term remission in schizophrenia and related psychoses with long-acting risperidone: results obtained in an open-label study with an observation period of 18 months.

  2008cites this paper
• mproved symptom control , functioning and atisfaction in French patients treated with ong-acting injectable risperidone a rispéridone injectable à action prolongée méliore le contrôle des symptômes , le onctionnement et la satisfaction dans une opulation de patients français

  2008cites this paper
• Prise en charge du premier épisode psychotique : le patient partenaire

  2008cites this paper
• Reply to Comments by Dr Peng et al for "Pharmacokinetics Study for Hyperprolactinemia Among Schizophrenics Switched from Risperidone to Risperidone Long-Acting Injection"

  2008cites this paper
• SF-36 scales, and simple sums of scales, were reliable quality-of-life summaries for patients with schizophrenia.

  2008cites this paper
• Restless Legs Syndrome Caused by Quetiapine Successfully Treated With Ropinirole in 2 Patients With Bipolar Disorder

  2008cites this paper
• Efficacy and safety of risperidone long-acting injectable in stable psychotic patients previously treated with oral risperidone

  2007influential citation
• The attitude of patients towards antipsychotic depot treatment

  2007cites this paper
• Eficacia de los antipsicóticos: relación con la ocupación óptima de los receptores D2

  2007cites this paper
• Long-term safety and tolerability of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder.

  2007cites this paper
• Long-acting risperidone injection: efficacy, safety, and cost-effectiveness of the first long-acting atypical antipsychotic

  2007influential citation
• New for Old? Risperidone Long-Acting Injection in Older Patients

  2007cites this paper
• Longer time to antipsychotic treatment discontinuation for any cause is associated with better functional outcomes for patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder.

  2007cites this paper
• Dual Diagnosis of Substance Abuse and Schizophrenia: Improving Compliance with Pharmacotherapy

  2007cites this paper